Quince Therapeutics Inc (QNCX) News

Form 8-K/A - Current report: [Amend]

Quince Therapeutics to Participate at Investor Events in January 2024

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a...

Form 8-K - Current report

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Quince Therapeutics Completes Acquisition of EryDel S.p.A.

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a...

Quince Therapeutics to Advance Study of EryDex as FDA Lifts Application Hold

By Denny Jacob Quince Therapeutics said it intends to advance trials on EryDex following the U.S. Food and Drug Administration's hold being...

U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics...